Prognostic Value of Glasgow Prognostic Score in Lung Cancer
Author Information
Author(s): Forrest L M, McMillan D C, McArdle C S, Angerson W J, Dagg K, Scott H R
Primary Institution: University Department of Surgery, Royal Infirmary, Glasgow
Hypothesis
The study aims to examine the prognostic value of the Glasgow Prognostic Score (GPS) and performance status in patients with inoperable non-small-cell lung cancer (NSCLC).
Conclusion
The Glasgow Prognostic Score (GPS) at diagnosis is a significant predictor of survival in patients with inoperable NSCLC, while its predictive value diminishes during follow-up.
Supporting Evidence
- At diagnosis, the GPS was a significant predictor of survival with a hazard ratio of 2.32.
- 68% of patients had an elevated C-reactive protein concentration.
- 42% of patients received active treatment during the study.
Takeaway
Doctors can use a special score called the Glasgow Prognostic Score to better understand how long patients with lung cancer might live, especially when they first find out they are sick.
Methodology
Patients with inoperable NSCLC were studied prospectively, with measurements of performance status and blood parameters taken at diagnosis and again at 3–6 months.
Limitations
A high attrition rate resulted in only 38 patients being available for follow-up assessment.
Participant Demographics
The majority of participants were male, over the age of 60, with approximately half having stage IV disease.
Statistical Information
P-Value
P<0.001
Confidence Interval
95% CI 1.52–3.54
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website